Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

After-Hours Movers: Trade Desk Climbs After Results, Roblox and Coinbase Sink

Published 08/09/2022, 05:14 PM
Updated 08/09/2022, 05:16 PM
© Reuters. After-Hours Movers: Trade Desk Climbs After Results, Roblox and Coinbase Sink

Investing.com Staff -

Magic Empire Global Ltd (NASDAQ:MEGL) +30%; shares declined 89% intraday.

The Trade Desk Inc (NASDAQ:TTD) +16%; reported Q2 EPS of $0.20, in-line with the analyst estimate of $0.20. Revenue for the quarter came in at $377 million versus the consensus estimate of $364.87 million.GUIDANCE: The Trade Desk Inc. sees Q3 2022 revenue of at least $385 million, versus the consensus of $382.6 million.

Halozyme Therapeutics (NASDAQ:HALO) +8%; reported Q2 EPS of $0.53, $0.06 better than the analyst estimate of $0.47. Revenue for the quarter came in at $152.4 million versus the consensus estimate of $138.63 million. GUIDANCE: Halozyme Therapeutics sees FY2022 EPS of $2.10-$2.25, versus the consensus of $2.23. Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $610.9 million.

H&R Block (NYSE:HRB) +4.5%; reported Q2 EPS of $1.43, $0.19 better than the analyst estimate of $1.24. Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $996.33 million. GUIDANCE: H&R Block sees FY2022 EPS of $3.70-$3.95, versus the consensus of $3.46. H&R Block sees FY2022 revenue of $3.535-3.585 billion, versus the consensus of $3.41 billion.

Roblox Corp (NYSE:RBLX) -13%; reported Q2 EPS of ($0.30), $0.05 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $591.2 million versus the consensus estimate of $639.19 million. Average Daily Active Users (DAUs) were 52.2 million, up 21% year over year

Cano Health (NYSE:CANO) -8.8%; reported Q2 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $689.4 million versus the consensus estimate of $712.61 million. GUIDANCE: Cano Health sees FY2022 revenue of $2.85-2.9 billion, versus the consensus of $2.86 billion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Azenta Inc (NASDAQ:AZTA) -6.3%; reported Q3 EPS of $0.12, $0.02 better than the analyst estimate of $0.10. Revenue for the quarter came in at $133 million versus the consensus estimate of $138.73 million.

Coinbase (NASDAQ:COIN) -4%; reported Q2 EPS of ($4.98), may not compare the analyst estimate of ($2.44). Revenue for the quarter came in at $808.3 million versus the consensus estimate of $879.69 million.

 

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.